Join to View Full Profile
Duke Medical Ctr# 3951Durham, NC 27710
Phone+1 317-670-7833
Dr. Clarke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014- Duke University HospitalResidency, Internal Medicine, 2008 - 2011
Indiana University School of MedicineClass of 2008
Certifications & Licensure
NC State Medical License 2008 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) Start of enrollment: 2020 Jun 09
Publications & Presentations
PubMed
- Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, Ibiayi Dagogo-Jack, Raymond Esper
Journal of Thoracic Oncology. 2025-10-01 - Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.Xiuning Le, Jacqulyne P Robichaux, Monique Nilsson, R S K Vijayan, Ashwin Ravichandran
Nature Communications. 2025-09-24 - Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives.Diamone Gathers, Cameron Oswalt, Laura Alder, Kevin Chen, Jordyn P Higgins
Cancers. 2025-06-21
Lectures
- Real-world (rw) clinical outcomes for advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) treated with second line (2L) ramucirumab plus docetaxel (...2019 ASCO Annual Meeting - 6/1/2019
- Real-world tumor response (rwTR) to ramucirumab plus docetaxel (R+D) post platinum-based (Pt) and immune checkpoint inhibitor (ICI) therapy in advanced non-small cell ...2019 ASCO Annual Meeting - 6/1/2019
- Veliparib in combination with nivolumab and platinum doublet chemotherapy (CT) in metastatic/advanced NSCLC.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 MutationsNovember 7th, 2019
Spectrum Announces Expansion of the Poziotinib Clinical ProgramJuly 22nd, 2019- OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerMay 8th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
